Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: First experience;Angiogene Faktoren zur Diagnosesicherung bei Präeklampsie in der klinischen Routine: erste Erfahrungen

Zeitschrift fur Geburtshilfe und Neonatologie

Volumn 214, Issue 6, 2010, Pages 234-238

  Stepan, H ^a   Schaarschmidt, W ^a   Jank, A ^a   Verlohren, S ^b   Kratzsch, J ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

aid in diagnosis; angiogenic factors; preeclampsia

Indexed keywords

ANGIOGENIC PROTEIN; FLT1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD; FEMALE; HUMAN; PILOT STUDY; PREECLAMPSIA; PREGNANCY;

ADULT; ANGIOGENIC PROTEINS; FEMALE; HUMANS; MEMBRANE PROTEINS; PILOT PROJECTS; PRE-ECLAMPSIA; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 78650950716     PISSN: 09482393     EISSN: 14391651     Source Type: Journal    
DOI: 10.1055/s-0030-1262827     Document Type: Article

References (15)

1. ACOG Practice Bulletin No. 3. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002 99 159-167
2. Roberts JM, Pearson GD, Cutler JA, et al. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertens Pregnancy 2003 22 109-127
3. DGGG-Leitlinie Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen AWMF 015/018 (S2): http://www.dggg.de/fileadmin/ public-docs/Leitlinien/g-03-03-05-diagnostik-therapie-hypertensiver.pdf
4. Milne F, Redman C, Walker J, et al.PRECOG II Group. Assessing the onset of pre-eclampsia in the hospital day unit: summary of the pre-eclampsia guideline (PRECOG II). BMJ 2009 Sep 9 339 b3129
5. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005 46 1077-1085
6. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005 48 372-386
7. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003 111 649-658
8. Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors and preeclampsia. Front Biosci 2007 12 2395-2402
9. Stepan H, Jank A. Angiogene Faktoren und ihre Rolle in der Entstehung und Vorhersage der Präeklampsie. Z Geburtshilfe Neonatol 2009 213 3 101-105
10. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004 350 672-683
11. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008 21 9-23
12. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006 355 992-1005
13. Stepan H, Geipel A, Schwarz F, et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008 198 175 e171-175 e176
14. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. American Journal of Obstetrics and Gynecology 2010 202 161.e1-161.e11 Epub 2009 Oct 21
15. Stepan H, Unversucht A, Wessel N, et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007 49 818-824